Secondary Klebsiella pneumoniae infection in patients with COVID-19: A systematic review.

Secondary Klebsiella pneumoniae infection in patients with COVID-19: A systematic review.

Publication date: Feb 01, 2024

This study aims to investigate the development of secondary bacterial infection and risk factors associated with it in critical COVID-19 patients, and to identify the most common pathogen groups in them. All the cohort studies were retrieved from Scopus, Google Scholar, Web of Science, and MEDLINE from the inception of COVID-19 to 2022 for the following keywords: ‘Klebsiella” AND “COVID-19”. The most common comorbidities among the patients with COVID-19 were respiratory disease (33. 62%), obesity (28. 99%), and heart disease or cardiovascular disease (16. 31%). We report 42. 91% rate of Klebsiella spp co-infection in ICU admission patients, mostly related to K. pneumonia (26. 81%), K. aerogenes (9. 4%), and K. oxytoca (6. 7%). The overall incidence of bacterial infection in hospitalized COVID-19 patients is estimated at 15. 5% and in 32. 5% of cases of co-infection patients deceased. The threat of carbapenem-resistant K. pneumoniae infections in patients with COVID-19 is imminent, therefore rational antibiotic therapy based on antibiotic sensitivity test should be implemented.

Concepts Keywords
Carbapenem Bacterial infections
Google COVID-19
Obesity K. pneumoniae
Pneumoniae Risk factors
Therapy

Semantics

Type Source Name
disease MESH infection
disease MESH COVID-19
disease MESH bacterial infection
disease IDO pathogen
disease MESH obesity
disease MESH heart disease
disease MESH cardiovascular disease
disease VO report
disease MESH co-infection
disease MESH pneumonia

Original Article

(Visited 1 times, 1 visits today)